Britain and America have concluded a major bilateral deal that will preserve zero levies on British drug exports going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the NHS. This move secures that import taxes on these key goods will be held at nothing for a timeframe of the next three years.
This agreement comes after earlier threats to dramatically increase tariffs on branded drug imports, with increases floated up to one hundred percent.
"This arrangement between the Britain strengthens the international landscape for new treatments and introduces much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the United States, which is by far the primary market for large companies like GSK and AstraZeneca.
Statistics show that in the one-year period prior to last September, the UK sold drugs valued at over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that timeframe.
"This agreement secures employment, boosts funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The pact involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double overall public funding on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Previously, rebates exceeded 20%.
Broader Context
The deal follows a long-running tension between the drug companies and the UK government over drug pricing and regulatory access.
These tensions were intensified by assertions that American patients were charged a premium for the identical medicines than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while substantial investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
